Trials / Completed
CompletedNCT00221104
Japan Statin Treatment Against Recurrent Stroke (J-STARS)
Secondary Prevention With HMG-CoA Reductase Inhibitor Against Stroke
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,578 (actual)
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Academic / Other
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Although hyperlipidemia is not always the risk factor of stroke, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can decrease the incidence of stroke in the patient with ischemic heart disease. The neuroprotective mechanism beyond cholesterol lowering should be expected to attenuate inflammation and atherosclerosis. The present study hypothesizes if pravastatin prevents recurrent stroke in the ischemic stroke patients with safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pravastatin |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2014-07-01
- First posted
- 2005-09-22
- Last updated
- 2018-01-25
- Results posted
- 2018-01-25
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00221104. Inclusion in this directory is not an endorsement.